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Resumen 
Introducción: en pacientes infectados crónicamente por el virus de la hepatitis C (VHC), la dieta occidental y el perfil metabólico parecen aumentar 
la fibrosis hepática (FH), sin embargo existe poca información sobre los componentes de la dieta y su papel en este contexto. 
Objetivos: evaluar la ingesta dietética, el perfil metabólico, la presencia de síndrome metabólico (SAT) y el riesgo cardiovascular en pacientes 
con VHC crónico según la presencia de fibrosis. 
Métodos: estudio transversal en el que se evaluaron 58 pacientes con VHC sin terapia antiviral activa ni cirrótica. Todos los pacientes fueron 
sometidos a evaluación clínica, de laboratorio y dietética, y fueron clasificados según la puntuación METAVIR. Los pacientes se dividieron según 
la presencia de FH. 
Resultados: en esta muestra el 55% de los pacientes eran mujeres, con edad promedio de 51,6 ± 9,7 años, siendo el 79,3% portadores 
del genotipo 1 del VHC. Los alimentos de los pacientes con FH presentaron una mayor proporción de energía y grasa, así como mayor carga 
glucémica en comparación con las personas sin FH. Los pacientes con circunferencia de la cintura presentaron mayor presión arterial sistólica 
y diastólica y mayores niveles de insulina. 
Conclusión: en conclusión, los pacientes con FH presentaron un consumo mayor de energía y grasas diario total, y peor perfil metabólico, 
caracterizado por mayor resistencia a la insulina y presión arterial.
Abstract 
Introduction: Occidental diet and metabolic profile seems to increase hepatic fibrosis (HF) in patients with chronic hepatitis C virus (HCV) infection, 
but there is scarce information about the diet components and their role in this setting. 
Objectives: This study aims to evaluate the dietary intake, metabolic profile, presence of metabolic syndrome (MetS) and cardiovascular risk in 
patients with chronic HCV infection according to the presence of fibrosis. 
Methods: Cross-sectional study which 58 patients with HCV infection without active antiviral therapy and non-cirrhotic were assessed. All 
patients were subjected to clinical, laboratorial and dietary evaluation, and classified according to the METAVIR score. Patients were divided as 
the presence of hepatic fibrosis. 
Results: In this sample, fifty-five percent of patients were females, the average age was 51.6 ± 9.7 years, and 79.3% were carriers of HCV 
genotype 1. Patients with HF presented higher energy, and fat intake as well as higher glycemic load of meals in comparison to those without 
HF. Patients with HF presented higher systolic and diastolic arterial pressure and higher levels of insulin. 
Conclusions: In conclusion, patients with HF had higher total daily energy and total fat intakes, and worse metabolic profile, characterized by 
a higher insulin resistance and blood pressure.
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INTRODUCTION
The hepatitis C virus infection (HCV) is a serious global public 
health problem, with a high social and economic impact, since 
chronic HCV infection is closely related to liver fibrosis, cirrhosis 
and also to the risk of hepatocellular carcinoma. Furthermore, 
HCV has notable metabolic consequences, with glycemic and lipid 
disturbances and may be associated to cardiovascular risk (1,2).
The hepatic fibrosis (HF) is characterized by the accumulation 
of scar tissue in response to persistent chronic hepatic injury. A 
number of factors can influence HCV fibrosis progression such 
as: age over 40 years old, male gender, hepatic steatosis, insu-
lin resistance (IR), immunosuppression, and necroinflammatory 
activity, among others (3). Moreover, even with the new potent 
direct antiviral drugs, a weight greater than 75kg and advanced 
fibrosis continue to be negative factors for a sustained virological 
response (3). 
Metabolic syndrome (MetS), that includes glucose abnormali-
ties, central obesity, dyslipidemia and hypertension, is a common 
disorder resulting from diabetes and obesity epidemic worldwide. 
There is a close relationship between HCV infection and MetS, 
and individual components of MetS are independent predictors 
of mortality in patients with chronic liver disease, including those 
infected with HCV (4). 
The adoption of a healthier lifestyle, with regular physical activi-
ty, diets with normal fat content, and maximum of 10% of saturat-
ed fats, seems to improve the metabolic profile, and even prevent 
hepatic steatosis and non-alcoholic steatohepatitis (5). Beyond 
that, diet components such as carbohydrates, lipids, polyunsat-
urated fatty acids, and also alcohol consumption were described 
as independent factors of liver damage (6).
There is scarce information about the role of the diet profile on 
HF in chronic HCV infected patients. Therefore, this study aimed 
to evaluate dietary intake, metabolic profile, presence of MetS 
and cardiovascular risk in these patients in accordance with the 
presence of fibrosis. 
MATERIALS AND METHODS
This cross-sectional study was conducted in adult patients 
(more than 18 years-old), chronically infected by HCV, genotypes 
1, 2 or 3, all of them attending the Gastroenterology Division’s 
outpatient clinic at Hospital de Clínicas de Porto Alegre (HCPA), 
Brazil, from October 2013 to July 2014. The study was conducted 
according to the guidelines laid down in the Declaration of Helsinki 
and all procedures involving human patients were approved by 
the HCPA Research Ethics Committee, number 13-0281. Written 
informed consent was obtained from all patients. 
HCV infection was confirmed by anti-HCV ELISA 3 and by the 
detection of viral RNA through real-time polymerase chain reaction 
(HCV RNA PCR). A liver biopsy was performed in every patient up 
to one year before inclusion in the study. Only specimens with 
more than 10 portal spaces were considered. The samples were 
analyzed by the same experienced pathologist, without the knowl-
edge of individual details of each case. The samples were classi-
fied accordingly to the METAVIR score: F0 = absence of fibrosis; 
F1 = portal fibrosis without septum; F2 = portal fibrosis with 
rare septum; F3 = numerous septum without cirrhosis; and F4 
= cirrhosis (7). Patients with alcohol intake (over 10 g of ethanol/
day) (8), cirrhosis, hepatocellular carcinoma or other malignant 
tumors, as well as those coinfected with HIV or hepatitis B virus, 
transplant recipients, pregnant women and those undergoing any 
active antiviral were not included. Patients were separated into 
two groups according to METAVIR score: Group absence of fibrosis 
(score = F0) and Group HF (scores F1 to F3).
DIETARY ASSESSMENT
The patient’s usual diet was assessed by 3-day-diet-record (two 
non-consecutive weekdays and one-weekend day). Records were 
analyzed using the Nutribase 2007 software (Clinical Nutritional 
Manager v.7.14; Cybersoft Phoenix, AZ, USA) (9). Data intake from 
nutrients were expressed in crude amounts (g/day, mg/day mcg/
day or IU/day) or in grams per kilogram of body weight. The data 
relating to food consumption were obtained throughout the study 
during different seasons.
The type and content of dietary fibers was estimated according 
to the data provided in the CRC Handbook of Dietary Fiber in 
Human Nutrition (10). In the present study, the fibers were classi-
fied into two major groups depending on their solubility in water. 
The 24-h glycemic index (GI) was estimated by the weighted GI 
value of each consumed food at 24-h and expressed as percent-
age. The values of the GI and available carbohydrates of each food 
were obtained and glucose was used as the reference food (11). 
Dietary glycemic load was calculated as the product of dietary GI 
and total carbohydrate intake divided by 100.
ANTHROPOMETRIC MEASUREMENTS
The body weight and height of patients (without shoes or 
coats) were obtained using an anthropometric scale, with mea-
surements recorded to the nearest 100 g for weight and to the 
nearest 0.1 cm for height. Body mass index (BMI) was calculated 
as weight (kilograms) divided by height (meters) square. The waist 
circumference was measured at the midpoint between the last 
rib and the iliac crest) by the World Health Organization (WHO) 
(12); flexible, non-stretch fiberglass tape measure was used for 
measurements.
LABORATORY MEASUREMENTS
Blood samples were obtained after a 12-h fast, between sev-
en and fifteen days after inclusion in the study: the following 
tests were then performed: aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), gamma glutamyl transpeptidase 
(GGT), ferritin, triglycerides and total cholesterol, cholesterol 
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HDL, C-reactive protein (CRP), insulin, serum glucose, choles-
terol LDL – calculated by the Friedewald formula: Cholesterol 
LDL = cholesterol total – (cholesterol-HDL – TG ÷ 5). The esti-
mated insulin resistance (IR) was calculated by the HOMA-IR by 
the following formula: HOMA = fasting insulin (μU/ml) X fasting 
glycaemia (mmol/l)/22.5.
CARDIOVASCULAR RISK ASSESSMENT
Cardiovascular risk was assessed by calculating the Framing-
ham score (13), which predicts a 10-year risk of suffering a car-
diovascular event on the basis of the following factors: age, total 
cholesterol, HDL cholesterol, systolic arterial blood pressure and 
presence/absence of diabetes mellitus and smoking.
METABOLIC SYNDROME 
The criteria for the clinical diagnosis of the MetS according 
to the Consensus (14) definition are the following: presence of 
3 or more of these factors: waist circumference ≥ 94 cm for 
men and ≥ 80 cm for women, arterial blood pressure ≥ 130/85 
mmHg or taking medications for blood pressure, triglycerides  
≥ 150 mg/dl or taking fibrates, HDL cholesterol < 40 mg/dl 
for men and < 50 mg/dl for women or taking pharmacological 
therapy, and fasting glucose ≥ 100 mg/dl or a diagnosis of 
diabetes. 
LEPTIN
Serum leptin levels were determined by a solid phase ELISA 
based on the sandwich principle (BioSource), accordingly with the 
manufacturer instructions. 
SAMPLE SIZE
Sample size calculation was based on the results from the study 
conducted by Petit et al. (15), that compared BMI and insulin 
among HCV infected patients with and without non-alcoholic fatty 
liver disease (NAFLD). It was calculated a sample size assuming 
a power of 80%, and an alpha of 5%.
STATISTICAL ANALYSIS
The results were expressed as an average ± SD for the quantita-
tive variables, and as frequencies and percentages for the qualitative 
variables. The evaluations of the differences between the quantitative 
variables were analyzed with the Student´s t test or Mann-Whitney 
U test. For the qualitative variables, the chi square test (χ2) or where 
appropriate, the Fisher exact test was used. Results were considered 
statistically significant with values of p < 0.05. 
RESULTS
DEMOGRAPHIC DATA 
Fifty-eight patients with chronic HCV infection were analyzed. 
Almost half of participants (46.6%) are classified as lower middle 
class, 39.7% have studied up to middle school and most of them 
(70.7%) live in urban area.
CLINICAL ASSESSMENT
Thirty-nine patients (67.2%) presented distinct levels of fibrosis. 
F1 (37.9%), F2 (27.6%) and F3 (1.7%). There was a predomi-
nance of females in the two groups, with the average age being 
similar between them. Significantly, higher values of systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) were observed 
in the group of patients with fibrosis. Regarding the investigation 
of alcohol consumption, 8.6% of patients reported occasional con-
sumption, equivalent to 2 drinks per week, while the remaining 
patients reported not use any type of alcoholic beverage. The 
complete description of clinical characteristics of patients is pre-
sented in table I.
LABORATORIAL MEASUREMENTS 
The HF group showed significantly higher levels of glycaemia, 
insulin, HOMA-IR, ferritin and, hemoglobin. The other laborato-
ry measurements (hematocrit, total cholesterol, HDL, LDL, tri-
glycerides, AST, ALT and GGT) did not differ statistically between 
the groups (Table I). When the increase of HOMA_IR is observed, 
there is also an increase in Ferritin levels between the patients 
in the sample, 3.18 (0.48-12.40) and 317.10 (28.90-881.91), 
respectively (p = 0.05). Eighteen Patients with HF (46.2%) have 
MetS, however there was no statistical difference between the 
groups. 
The leptin serum levels did not differ between chronic HCV 
infected patients with and without fibrosis, though women and 
men had different levels: 28.5 (15.8-33.1) versus 7.2 (5.1-
9.3), as well as eutrophic and overweight/obesity patients: 7.2 
(4.4-11.7) versus 22.8 (8.3-31.4), respectively, with p < 0.001 
for all.
DIETARY INTAKE x HEPATIC FIBROSIS
The patients with HF presented a significantly higher total daily 
energy and fat (g/kg/day) intakes. The glycemic load of meals was 
also higher in this group of patients. The other components of diet 
(carbohydrate, protein, cholesterol, fiber, calcium, zinc, iron, folic 
acid, niacin, thiamine, vitamin A, vitamin C, vitamin B6, vitamin 
B12 and vitamin D) did not show significant differences between 
the groups (Table II).
143
[Nutr Hosp 2018;35(1):140-147]
IS DIETARY GLYCEMIC LOAD ASSOCIATED WITH LIVER FIBROSIS IN HEPATITIS C?
Table I. Clinical and laboratory characteristics of chronic HCV infected patients in 
accordance with the presence of hepatic fibrosis
Absence HF
n = 19
Presence HF
n = 39
p-value
Gender (female) 13 (68.4%) 19 (48.7%) 0.157b
Ethnicity (Caucasian) 15 (78.9%) 31 (79.5%) 0.795b
Age (years) 47.8 ± 12.3 53.4 ± 7.6 0.079a
Genotype: 0.078a
 1 14 (77.8%) 32 (82.1%)
 2 0 (0.0%) 1 (2.6%)
 3 4 (22.2%) 6 (15.4%)
Physical activity: 0.198b
 Sedentary/irregularly active 11 (57.9%) 22 (56.5%)
 Economic classification (B2)d 7 (36.8%) 9 (23.1%) 0.673b
 SBP (mmHg)e 129.5 ± 17.7 140.1 ± 18.9 0.046a
 DBP (mmHg)f 78.0 ± 8.2 84.8 ± 10.7 0.010a
Framingham Scoreg: 0.114b
 High risk (> 10%) 6 (31.6%) 23 (59.0%)
High waist circunference*: 0.137b
 Female 6 (18.8%) 11 (42.3%)
Metabolic syndrome 4 (21.1%) 18 (46.2%) 0.087b
Body mass index (kg/m2) 26.8 ± 2.1 27.5 ± 4.6 0.440a
Glucose (mg/dL) 86 (82-9) 94 (89-102) 0.001c
Insulin (µUI/mL) 10.7 (8.2-14.7) 15.3 (10.2-26.0) 0.009c
HOMA_IR 2.18 (1.6-3.3) 3.4 (2.4-6.4) 0.002c
Ferritin (µg/mL) 143.8 ± 33.0 378.8 ± 200.1 0.009a
Albumin (g/dL) 4.2 (4.1-4.4) 4.4 (4.2-4.5) 0.021c
Hematocrit (g/dL) 40.6 (38.8-41.5) 42.8 (39.3-45.8) 0.050c
Hemoglobin (g/dL) 13.9 (13.2-14.7) 14.8 (13.9-15.8) 0.031c
Triglycerides (mg/dL) 87 (63-101) 97 (75-122) 0.097c
Cholesterol Total (mg/dL) 166.0 ± 25.3 165.1 ± 26.9 0.901a
HDL-cholesterol (mg/dL) 48.5 ± 12.6 43.0 ± 10.2 0.083a
LDL-cholesterol (mg/dL) 100.0 ± 23.8 99.8 ± 26.0 0.977a
CRP (mg/L)h 4 (4-4) 4 (4-4) 0.541c
AST (U/L)i 39 (29-55) 45 (35-74) 0.125c
ALT (U/L)j 46 (32-74) 56 (39-104) 0.074c
Gama GT (U/L)k 59.9 ± 13.7 77.5 ± 12.4 0.158a
at test.; bχ²; cMann-Whitney; dBrazil Economic Classification Criteria (ABEP, 2008); eSystolic blood pressure; fDisastolic blood pressure; gCardiovascular disease risk 
estimate, percentage in 10 years, calculated according to Framingham study, 2008; hC-reactive protein; iAspartate aminotransferase; jAlanine aminotransferase; 
kGama glutamyl transpeptidase; IHepatic fibrosis.
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ASSESSMENT OF HEPATIC STEATOSIS 
Additionally, hepatic steatosis was evaluated in 54. In only eight 
cases (13.8% of samples) steatosis was found: minimal (0 to 5%) 
in five, and mild (5 to 33%) in three. No patient in the study had 
diagnostic criteria for non-alcoholic steatohepatitis. 
DISCUSSION
In the present study, an increased total energy and fat intakes 
among chronic HCV infected patients was observed, this con-
sumption being especially evident in patients with HF. Fioravante 
et al. (16) described similar findings in relation to diet; however, 
the authors did not evaluate differences as to the presence of HF. 
Another research (5) also assessed patients with chronic HCV 
infection, however, the patients included in their study presented a 
Table II. Daily intake of nutrients of chronic HCV patients in accordance  
with the presence of hepatic fibrosis
Absence HFc
n = 19
Presence HF
n = 39
p-value
Energy (Kcal/kg/day) 28.8 ± 7.9 34.6 ± 11.2 0.048a
Carbohydrates (g/kg) 3.2 (2.6-3.8) 3.7 (2.6-5.0) 0.187b
Proteins (g/kg) 1.2 (0.9-1.7) 1.3 (0.9-1.9) 0.588b
Lipids (g/kg) 1.1 (0.8-1.3) 1.4 (1.0-1.9) 0.010b
Cholesterol (mg) 264.7 (149.9-367.2) 272.3 (173.3-358.6) 0.909b
Total Fiber (g/day) 12.6 (9.7-15.8) 15.5 (10.7-21.4) 0.221b
Soluble Fiber (g/day) 3.7 (3.3-5.8) 5.2 (3.4-6.5) 0.221b
Insoluble Fiber (g/day) 8.9 (6.5-11.4) 10.2 (7.3-14.7) 0.282b
Glycemic Load (g) 181.0 (140.5-223.4) 221.9 (168.9-307.8) 0.046b
Glycemic Index (%) 61.1 (56.9-62.5) 61.0 (57.2-64.3) 0.740b
Calcium (mg) 694.57 ± 288.14 714.63 ± 323.75 0.820a
Zinc (mg) 12.74 ± 5.39 14.38 ± 6.47 0.346a
Iron (mg) 13.90 ± 5.49 15.00 ± 4.96 0.446a
Folic Acid (mcg) 166.11 ± 94.06 156.23 ± 78.07 0.674a
Niacin (mg) 21.81 ± 7.93 24.54 ± 9.92 0.300a
Thiamine (mg) 1.64 ± 0.84 1.70 ± 0.61 0.746a
Vitamin C (mg) 10.91 (41.77-146.98) 94.94 (42.10-173.93) 0.270b
Vitamin A (IU) 4370.43 (2146.27-7427.93) 3853.70 (2088.92-8217.622) 0.987b
Vitamin B6 (mg) 1.65 ± 0.63 1.80 ± 0.7 0.440a
Vitamin B12 (mcg) 4.07 (2.84-5.88) 3.59 (3.05-5.58) 0.866b
Vitamin D (IU) 13.33 (0-84) 44.00 (0-74.66) 0.371b
at Test, bMann-Whitney; cHepatic fibrosis.
significant alcohol consumption, about 40 g of ethanol/day, while, 
in our study most of patients did not consume any alcohol.
As for the glycemic load of the meals, which translates as the 
product of the GI and the total carbohydrate consumed, it was 
observed that in the HF group, it was greater. Meals with a high 
glycemic load give a reduced level of fullness and are usually 
associated with an excessive ingestion of food, which may con-
tribute to an increase in body fat and a higher IR (17). In contrast, 
meals with a low glycemic load can improve IR, since smaller 
quantities of insulin are required, as well as promoting smaller 
variations in glycemia (18,19). To the best of our knowledge, this 
is the first study who analyzed the glycemic load in HCV infect-
ed patients. Balanced food intake may modulate the severity of 
NAFLD development. The association between a high intake of 
saturated fat, low fiber intake and high intake of fructose leads 
to a more serious manifestation of NAFLD (20). The role of fruc-
tose intake is associated with the development IR, fatty liver, and 
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hepatic damage in experimental studies, and a clinical study con-
firmed that a diet rich in fructose-sweetened beverages was also 
associated with increased insulin resistance (21,22). 
Although we show a greater intake of calories and fats by the 
patients with fibrosis, differences in relation to body weight in the 
groups of patients were not observed, considering that the mea-
sured weight was liquid and ascites free. Moreover, we can infer 
that components of diet have a more important role than weight 
in the process of liver disease. 
Since patients with fibrosis evaluated in this study presented 
higher serum glucose and insulin levels Fibrosis itself seems to be 
important to the relationship with IR and type 2 diabetes mellitus 
(19). Hui et al. (23) described higher HOMA-IR levels, in patients 
carrying chronic hepatitis C, without fibrosis (degree of F0) com-
pared to patients with fibrosis (F1-F3) and to healthy individuals, 
alerting to the fact that even in the early stages of disease, the IR 
may be present. Moreover, a meta-analysis of more than 2,700 
patients indicated that the IR reduces the rates of sustained viro-
logical response in patients treated with pegylated interferon and 
ribavirin regardless of genotype (24).
In this study, increased levels of ferritin in patients with fibro-
sis were also found, similar to the findings of Petta et al. (25). 
For the analysis of pathology, we can tell our patients had iron 
storage related liver disease. Hyperferritinemia thus is probably 
related to chronic inflammation, secondary to hepatitis C, not to 
excess iron. Other authors demonstrated increased ferritin levels 
in hepatitis C (1). 
Insulin resistance is a recognized extrahepatic manifestation 
of hepatitis C, as the virus promotes the secretion of soluble 
mediators that act on glucose homeostasis (extrahepatic insulin 
resistance) and also has direct interference with insulin signal-
ing (intravenous insulin resistance-hepatic) (26). In the present 
study, there was a relationship between insulin resistance and 
the presence of fibrosis, which suggests that some additional 
factor may be associated. Whether this factor is caloric intake, 
systemic inflammation or even both, there is no way to define. 
The fact is that as there is increased HOMA-IR increases ferritin, 
an acute phase marker, and suggesting increased inflammation. 
This ratio, however, was not maintained when inflammation was 
assessed by C-reactive protein. Perhaps this question deserves 
to be better explored in studies designed for this purpose, with a 
control group not infected by virus C.
The overall prevalence of hypertension in the patients studied 
was almost 40%, being that the patients with hepatic fibrosis 
presented higher average values of systolic blood pressure and 
diastolic blood pressure. The systemic arterial blood pressure is 
a factor in the metabolic syndrome, which in turn correlates to 
a faster evolution of fibrosis in patients with hepatitis C (27). In 
general, the pressure levels are associated with body weight, not 
evident in our study. 
MetS was detected in almost half patients with HF, but it was 
not found significant difference according to the presence of liv-
er fibrosis, as well as, it was not found in a cohort of 10,383 
patients with HCV infection (28). Studies have shown that there 
is a strong association between metabolic disorders and liver 
disease caused by chronic hepatitis C. This association tends 
to lead to worse prognosis. Patients with both comorbidities had 
lower treatment response against HCV and faster progression to 
cirrhosis and hepatocarcinoma compared to those chronic HCV 
infected patients without MetS (29).
Behavioral factors are involved in the pathogenesis of NAFLD, 
therefore, an increased dietary intake, especially an elevated 
intake of total energy and fat, can be considered as risk factors 
for disease progression (30); besides the fact that HCV infection 
per se can be responsible for glucose metabolism and lipid profile 
disorders (31). It has been demonstrated that an increased in the 
fat intake is also associated to a greater incidence of cirrhosis and 
liver cancer, by induction of hepatic steatosis and fibrosis (32), 
once the excess calories in the diet are stored principally as tri-
glycerides, which accumulate in the liver (33). On the other hand, 
dietary interventions in the management of patients with NAFLD 
demonstrated that a diet low in carbohydrates (20 g/day) (34), 
energy restriction and adoption of a Mediterranean style diet (6) 
were effective in promoting the reduction of hepatic triglycerides, 
contributing significantly to the reduction of hepatic steatosis and 
improvement of insulin sensitivity. 
Despite an increased fat intake shown in this study, increased 
rates of steatosis were not found. The low rate of steatosis 
(13.8%) can be explained in part by the fact that most includ-
ed patients were infected by genotype 1, and not by genotype 
3, that is recognized as being more steatogenic (35). Although 
finding low steatosis prevalence on the sample, patients with HF 
were related to dietary and metabolic factors, so it is suggest-
ed that steatosis itself should not be the only factor associated 
with increased development of fibrosis. Inflammation could be an 
independent factor.
In our study, leptin levels were analyzed, however it was not 
find any association with the presence of HF. Similar findings 
were shown by Muzzi et al. (36) that evaluated the leptin lev-
els in 221 patients with hepatitis C, however, there were no 
differences as to the plasma leptin levels, irrespectively of the 
presence/absence of steatosis and/or fibrosis. The role of leptin 
is still controversial, with studies suggesting that this hormone 
promotes hepatic steatosis and steatohepatitis, and others 
showing that leptin levels correlate with steatosis, but not with 
inflammation and fibrosis (37). 
Regarding waist circumference, most males showed higher 
values than recommended. Abdominal fat, irrespective of total 
fat volume, is an independent predictive factor of fat buildup in 
hepatocytes, with a crucial role in the pathogenesis of NAFLD. 
Lipid stocks can reach toxic levels, increasing oxidative stress, 
with formation of free radicals, mitochondrial damage, inflamma-
tion and even fibrosis (38)
. 
Furthermore, obesity and, more spe-
cifically, intra-abdominal fat, is positively associated with IR and 
MetS, both related with faster progression to fibrosis in patients 
with HCV (39). This study found a high prevalence of MetS in the 
sample. This can be justified because of the hepatitis C virus is 
associated with IR, an important feature of MetS and present 
in many of these patients, both (Mets and IR) play a role in the 
progression of HCV (40).
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Although it was found high prevalence of elevated cardiovascu-
lar risk in this study, there was no significant difference between 
patients with and without fibrosis. Indeed, 70% of the patients 
assessed in this study exhibited moderate or high risk of suffering 
a cardiovascular event within 10 years, similar to results reported 
for diabetic patients and patients with metabolic syndrome (41). 
STRENGTHS AND LIMITATIONS
Possible limitations of this study are related to unintentional 
predominance of patients with genotype 1, this fact limits the 
generalization of our results to patients with other genotypes. Fur-
thermore, regarding data from dietary intake, food records were 
obtained throughout the study and not in a single season, but as 
the patients were evenly distributed in the months of the study, 
we believe that this fact has not affected the results.
Another restriction that could preclude generalization of our 
data is associated with the number of participants, however it was 
reached the planned sample size calculation. Patients were carefully 
selected to avoid confounding factors (especially alcohol intake, 
cirrhosis and active antiviral treatment); especially this last item 
was a difficult obstacle along the data collection, since most of the 
patients attending the Gastroenterology Division’s outpatient clinic 
were using antiviral drugs and could not be included. On the other 
hand, these factors strengthened data obtained by relating the diet 
with liver fibrosis. The strong point of this work is the dietary eval-
uation and it relationship with HF; until now there was not another 
study that had evaluated the glycemic load meals of these patients. 
Our data could prove of great value for taking the decision to adopt 
more specific interventions for HCV patients, especially with empha-
sis on energy and lipid restrictions, and also on carbohydrates type, 
considering the glycemic index and glycemic load.
CONCLUSIONS
In conclusion, patients with HF presented elevated total daily 
energy and total fat intakes, a higher glycemic load of meals, 
as well as a worse metabolic profile, with higher rates of insu-
lin resistance and increased pressure levels, when compared to 
patients without fibrosis. These metabolic alterations associated 
to chronic infection by HCV tend to worsen the prognosis of liver 
disease, reinforcing the need for early diagnosis and treatment of 
the disease, including dietary management of patients to minimize 
morbidity and mortality.
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